Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Assets Average (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Assets Average for 15 consecutive years, with $50.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 19.32% to $50.5 million in Q4 2025 year-over-year; TTM through Oct 2025 was $50.5 million, a 19.32% decrease, with the full-year FY2025 number at $57.5 million, down 13.6% from a year prior.
  • Assets Average was $50.5 million for Q4 2025 at PharmaCyte Biotech, up from $50.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $92.1 million in Q1 2022 to a low of $7.0 million in Q3 2021.
  • A 5-year average of $60.5 million and a median of $65.3 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 1167.73% in 2022, then tumbled 34.15% in 2025.
  • PharmaCyte Biotech's Assets Average stood at $49.5 million in 2021, then skyrocketed by 71.54% to $84.9 million in 2022, then fell by 6.47% to $79.4 million in 2023, then dropped by 21.08% to $62.6 million in 2024, then dropped by 19.32% to $50.5 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Assets Average are $50.5 million (Q4 2025), $50.1 million (Q3 2025), and $49.5 million (Q2 2025).